Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: Response profiles after primary infection and homologous rechallenge with strain H10407

Clinical and Vaccine Immunology

Volumn 23, Issue 1, 2016, Pages 55-64

  Chakraborty, Subhra ^a   Harro, Clayton ^a   DeNearing, Barbara ^a   Ram, Malathi ^a   Feller, Andrea ^a,c   Cage, Alicia ^a   Bauers, Nicole ^b   Bourgeois, A Louis ^a,b   Walker, Richard ^b   Sack, David A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b PATH   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL ANTIGEN; COLONIZATION FACTOR ANTIGEN I; ENTEROTOXIGENIC ESCHERICHIA COLI VACCINE; ESCHERICHIA COLI VACCINE; HEAT LABILE TOXIN B SUBUNIT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; TOXIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; ESCHERICHIA COLI PROTEIN; FIMBRIA PROTEIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL SHEDDING; BACTERIAL STRAIN; CONTROLLED STUDY; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INTERMETHOD COMPARISON; LAVAGE FLUID; PRIORITY JOURNAL; SALIVA; ANTIBODY PRODUCTION; BLOOD; CHEMISTRY; DIARRHEA; ESCHERICHIA COLI INFECTIONS; IMMUNOLOGY; MICROBIOLOGY; MUCOSAL IMMUNITY; PATHOGENICITY; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; DIARRHEA; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FECES; FIMBRIAE PROTEINS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; SALIVA;

EID: 84954357157     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00617-15     Document Type: Article

References (37)

1. Steffen R, Castelli F, Dieter NH, Rombo L, Zuckerman NJ. 2005. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 12:102-107. http://dx.doi.org/10.2310/7060.2005.12207.
2. Wennerås C, Erling V. 2004. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J Health Popul Nutr 22:370-382.
3. Isidean SD, Riddle MS, Savarino SJ, Porter CK. 2011. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 29:6167-6178. http://dx.doi.org/10.1016/j.vaccine.2011.06.084.
4. World Health Organization. 2009. Diarrhoeal diseases. Initiative for vaccine research (IVR).World Health Organization, Geneva, Switzerland. (Updated February 2009.) http://www.who.int/vaccine-research/diseases/diarrhoeal/en/index6.html.
5. Das JK, Tripathi A, Ali A, Hassan A, Dojosoeandy C, Bhutta ZA. 2013. Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Public Health 13(Suppl 3):S11.
6. Qadri F, Svennerholm AM, Faruque AS, Sack RB. 2005. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 18:465-483. http://dx.doi.org/10.1128/CMR.18.3.465-483.2005.
7. Hill DR, Beeching NJ. 2010. Travelers' diarrhea. Curr Opin Infect Dis 23:481-487. http://dx.doi.org/10.1097/QCO.0b013e32833dfca5.
8. Zhang W, Sack DA. 2012. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines 11:677-694. http://dx.doi.org/10.1586/erv.12.37.
9. Fleckenstein J, Sheikh A, Qadri F. 2014. Novel antigens for enterotoxigenic Escherichia coli vaccines. Expert Rev Vaccines 13:631-639. http://dx.doi.org/10.1586/14760584.2014.905745.
10. Black RE. 1993. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine 11:100-106. http://dx.doi.org/10.1016/0264-410X(93)90002-F.
11. Cravioto A, Reyes RE, Trujillo F, Uribe F, Navarro A, De La Roca JM, Hernandez JM, Perez G, Vazquez V. 1990. Risk of diarrhea during the first year of life associated with initial and subsequent colonization by specific enteropathogens. Am J Epidemiol 131:886-904.
12. Levine MM, Nalin DR, Hoover DL, Bergquist E, Hornick RB, Young CR. 1979. Immunity to enterotoxigenic Escherichia coli. Infect Immun 23:729-736.
13. Levine MM, Black RE, Brinton CC, Jr, Clements ML, Fusco P, Hughes TP, O'Donnell S, Robins-Browne R, Wood S, Young CR. 1982. Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man. Scand J Infect Dis Suppl 33:83-95.
14. Sack RB, Kline RL, Spira WM. 1988. Oral immunization of rabbits with enterotoxigenic Escherichia coli protects against intraintestinal challenge. Infect Immun 56:387-394.
15. Ahrén CM, Svennerholm AM. 1982. Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. Infect Immun 38:74-79.
16. Svennerholm AM, Steele D. 2004. Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol 18:421-445. http://dx.doi.org/10.1016/j.bpg.2003.11.004.
17. Walker RI, Steele D, Aguado T. 2007. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. Coli (ETEC) disease. Vaccine 25:2545-2566. http://dx.doi.org/10.1016/j.vaccine.2006.12.028.
18. Stoll BJ, Svennerholm AM, Gothefors L, Barua D, Huda S, Holmgren J. 1986. Local and systemic antibody responses to naturally acquired enterotoxigenic Escherichia coli diarrhea in an endemic area. J Infect Dis 153:527-534. http://dx.doi.org/10.1093/infdis/153.3.527.
19. Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA. 2011. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol 18:1719-1727. http://dx.doi.org/10.1128/CVI.05194-11.
20. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, Sack RB, Svennerholm A. 2000. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine 18:2704-2712. http://dx.doi.org/10.1016/S0264-410X(00)00056-6.
21. Porter CK, Riddle MS, Tribble DR, Louis Bougeois A, McKenzie R, Isidean SD, Sebeny P, Savarino SJ. 2011. A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine 29:5869-5885. http://dx.doi.org/10.1016/j.vaccine.2011.05.021.
22. Levine MM, Rennels MBL, Cisneros Hughes TP, Nalin DR, Young CR. 1980. Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact. Am J Epidemiol 111:347-355.
23. Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD. 2012. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 19:1921-1931. http://dx.doi.org/10.1128/CVI.00364-12.
24. Ahrén C, Jertborn M, Svennerholm AM. 1998. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulinAresponses in blood. Infect Immun 66:3311-3316.
25. Kantele A, Kantele JM, Arvilommi H, Makela PH. 1991. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine 9:428-431. http://dx.doi.org/10.1016/0264-410X(91)90130-X.
26. Qadri F, Ahmed T, Ahmed F, Bradley SR, Sack DA, Svennerholm AM. 2003. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine 21:2394-2403. http://dx.doi.org/10.1016/S0264-410X(03)00077-X.
27. Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, Burg EF, III, Moran AP, Applebee L, Bourgeois AL. 2010. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun 78:1750-1759. http://dx.doi.org/10.1128/IAI.01021-09.
28. Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM. 1995. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13:1488-1494. http://dx.doi.org/10.1016/0264-410X(95)00102-7.
29. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF, Jr, Abu-Elyazeed R, Rao M, Francis WM, El Mohamady H, Safwat M, Naficy AB, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD, Pride Study Group. 2002. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 21:322-330. http://dx.doi.org/10.1097/00006454-200204000-00012.
30. Jertborn M, Svennerholm AM, Holmgren J. 1984. Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. Int Arch Allergy Appl Immunol 75:38-43. http://dx.doi.org/10.1159/000233587.
31. Raqib R, Kamal SM, Rahman MJ, Rahim Z, Banu S, Bardhan PK, Chowdhury F, Ara G, Zaman K, Breiman RF, Andersson J, Sack DA. 2004. Use of antibodies in lymphocyte secretions for detection of subclinical tuberculosis infection in asymptomatic contacts. Clin Diagn Lab Immunol 11:1022-1027.
32. Manz RA, Hauser AE, Hiepe F, Radbruch A. 2005. Maintenance of serum antibody levels. Annu Rev Immunol 23:367-386. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115723.
33. Tarlinton D, Radbruch A, Hiepe F, Dorner T. 2008. Plasma cell differentiation and survival. Curr Opin Immunol 20:162-169. http://dx.doi.org/10.1016/j.coi.2008.03.016.
34. Raqib R, Mondal D, Karim MA, Chowdhury F, Ahmed S, Luby S, Cravioto A, Andersson J, Sack D. 2009. Detection of antibodies secreted from circulating Mycobacterium tuberculosis-specific plasma cells in the diagnosis of pediatric tuberculosis. Clin Vaccine Immunol 16:521-527. http://dx.doi.org/10.1128/CVI.00391-08.
35. Chisti MJ, Salam MA, Raqib R, Banu S, Shahid AS, Shahunja KM, Sharmin L, Ashraf H, Faruque AS, Bardhan PK, Ahmed T. 2015. Validity of antibodies in lymphocyte supernatant in diagnosing tuberculosis in severely malnourished children presenting with pneumonia. PLoS One 10:e0126863. http://dx.doi.org/10.1371/journal.pone.0126863.
36. Gaspari MM, Brennan PT, Solomon SM, Elson CO. 1988. A method of obtaining, processing, and analyzing human intestinal secretions for antibody content. J Immunol Methods 110:85-91. http://dx.doi.org/10.1016/0022-1759(88)90086-5.
37. Svennerholm AM, Sack DA, Holmgren J, Bardhan PK. 1982. Intestinal antibody responses after immunisation with cholera B subunit. Lancet i:305-308.